U
ARCT icon

UBS’s Arcturus Therapeutics ARCT Stock Holding History

UBS’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$325K Buy
3,009
+2,639
+713% +$344K ﹤0.01% 4694
2014
Q2 		$45K Buy
+370
New +$44.7K ﹤0.01% 6998
2014
Q1 		– Sell
-128
Closed -$16K – 10399
2013
Q4 		$16K Buy
+128
New +$16.1K ﹤0.01% 8409
2013
Q3 		– Sell
-58
Closed -$3K – 10326
2013
Q2 		$3K Buy
+58
New +$2.84K ﹤0.01% 9575

Other funds holding ARCT

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

UBS's ARCT Position: Q3 2014 in Review

UBS increased its Arcturus Therapeutics (ARCT) stake by 713% in Q3 2014, buying an estimated $344K and bringing the position to 3,009 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #4694.

UBS first reported a position in ARCT in Q2 2013 and has held it in 4 quarters since. 38 funds tracked by Wall St. Rank hold ARCT as of Q3 2014.

  • UBS held 3,009 shares of Arcturus Therapeutics worth $325K as of Q3 2014.
  • UBS bought 2,639 Arcturus Therapeutics shares in Q3 2014, an estimated $344K.
  • Arcturus Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4694 holding.
  • UBS first reported a position in Arcturus Therapeutics in Q2 2013 and has held it in 4 quarters since.
  • 38 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.